Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.

NCT02099617 is registered in ClinicalTrials.gov with Ceric Sàrl as lead sponsor.

NCT NCT02099617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02099617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.
Lead sponsor
Ceric Sàrl
Phase
Not applicable
Overall status
Completed
Start date
May 31, 2014
Completion date
June 30, 2018
Enrollment
1,200 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, silent myocardial ischemia, stable angina